SYDNEY, November 10 /PRNewswire/ --

- The Next Generation Healthcare Solution to Make Treatment More Personal and Efficient

- LORENZO Sets the Stage to Transform Healthcare Delivery Globally

iSOFT, an IBA Health Group Limited (ASX: IBA) company, today announced the global launch of LORENZO, the next generation software solution for healthcare organisations. LORENZO is a unique solution that will revolutionise the way healthcare is delivered around the individual.

I gets weary, and sick of trying … the words almost taken from Ol' Man River.  But weary of what?  Trying to persuade the physics world from harping too much on about celebrity physicists.  This they do (at least in my reading) to an extent grossly exceeding that of mathematicians and chemists.  “How will we discover the African Einstein?” they ask, to which I reply that a wilderness of Einsteins would do Africa no good at all, whereas a widespread knowledge of basic physics might help the continent somewhat.  Even if Mariah Carey’s new album E=MC² inspires some to take up physics, most will fall exhausted before reaching such high levels.

The seasons are shifting. For most places, colder weather and less daylight means the steady approach of winter. In my home in Northern California, summer lasts through October.  The sun shines steadily, temperature drops to a tolerable high 60’s and not a drop of rain is  seen. Suddenly,  it’s dark by 5:00pm and the cuffs of your pants are constantly wet from trudging through the rain puddles, you know that the dreaded winter is here.

In California, we definitely have seasons.

For those that suffer from Huntington’s Disease or worry about its development, a new hope for a treatment may be on the horizon. Raptor Pharmaceuticals Corp. has announced that it will collaborate with researchers from French university Centre Hospitalier Universitaire d’Angers (CHU d’Angers) on the development of its proprietary drug delayed-release cysteamine bitartrate (DR Cysteamine) in a Phase II clinical trial for treatment for patients with Huntington’s Disease.

MONTEREY, California, November 10 /PRNewswire/ --

PARI Pharma GmbH has successfully completed Phase I and Phase II clinical trials comparing its proprietary PARI Tobramycin 100 (150mg/1.5mL) formulation delivered via a customized Investigational eFlow Nebulizer System to TOBI (tobramycin 300mg/5mL) delivered with the PARI LC PLUS jet nebulizer. While key deposition and safety thresholds were maintained, the marked difference was a reduction in the average inhalation time to 4 - 4 1/2 minutes for the PARI Tobramycin 100, down from 16 - 17 minutes for the TOBI therapy. PARI Tobramycin 100 is an investigational therapy for cystic fibrosis patients with Pseudomonas aeruginosa infections.

HOUSTON, Texas, November 10 /PRNewswire/ -- AVEVA (LSE:AVV), the leading supplier of engineering IT systems for the plant and marine industries, today announced further expansion into Latin America with the opening of AVEVA do Brasil in Rio de Janeiro. This office, the latest in AVEVA's expanding global platform, will provide premium product solutions and support for its growing customer base in Brazil, including the country's leading energy company.

Richard Longdon, Chief Executive of AVEVA Group, said, As we look to the future of global energy and infrastructure development, we are continuing our strategy of increasing our presence in the BRICs - Brazil, Russia, India and China. Undoubtedly, it is an opportune time for our further expansion into the Latin American.

Resverlogix Corp announced today that treatment with its lead drug RVX-208, a first in class ApoA-I/Prebeta-HDL elevating drug, in a post-hoc analysis from the Phase 1a clinical trial found that treatment with RVX-208 resulted in a positive trend on an important marker of cognitive function and Alzheimer's disease, Amyloid-beta40 is an important constituent of amyloid plaques in the brains of Alzheimer's patients. The analysis of the plasma markers for Alzheimer's disease was performed by Dr. D. Larry Sparks, Senior Scientist and Head of the Roberts Laboratory for Neurodegenerative Disease Research at Sun Health Research Institute in Sun City, Arizona.

EINDHOVEN, Netherlands, November 10 /PRNewswire/ --

- With its LifeVibes(TM) Multimedia Software in Over 500 Million Devices, NXP Software has Established Itself as the Leader for Mobile Multimedia in Just 5 Years of Existence

EINDHOVEN, Netherlands, November 10 /PRNewswire/ --

Today marks NXP Software's 5th birthday. Since 2003, the company has established itself as the leading software provider for mobile multimedia, bringing vibrant experiences to millions of consumers. Its LifeVibes(TM) software now powers multimedia applications in more than 500 million mobile handsets worldwide, having over 250 design-ins on phone models from major OEMs.

COPENHAGEN, November 10 /PRNewswire/ --

- Responses Significantly Correlated to Overall Survival

- Summary: Three ofatumumab abstracts have been accepted for presentation at the ASH meeting December 6-9, 2008

Genmab A/S (OMX: GEN) announced today that three ofatumumab (HuMax-CD20(R)) abstracts have been accepted for presentation at the 50th American Society of Hematology Annual Meeting and Exposition (ASH) December 6-9, 2008. Updated interim efficacy data from the pivotal study evaluating ofatumumab to treat two groups of chronic lymphocytic leukemia (CLL) patients with an unmet medical need will be presented in an oral session. Headline interim data from the study was announced in July 2008.

CALGARY, Canada, November 10 /PRNewswire/ --

- 61 per cent Increase in Funds Flow From Operations to $539 million - 103 per cent Increase in Net Income to $248 million - 2 per cent Increase in Production to 131.3 Mbbl/d - $1.6 Billion Capital Investment Budget for 2009

CALGARY, Canada, November 10 /PRNewswire/ --

Addax Petroleum Corporation (Addax Petroleum or the Corporation) (TSX:AXC and LSE:AXC), today announced its results for the quarter ended September 30, 2008. The financial results are prepared in accordance with Canadian GAAP and the reporting currency is US dollars. In addition, the Corporation outlined its capital investment budget and production outlook for 2009.